Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun;27(6):213-222.
doi: 10.1097/FPC.0000000000000281.

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity

Signe Thiesen  1 , Peng Yin  2 , Andrea L Jorgensen  2 , Jieying Eunice Zhang  1 , Valentina Manzo  1   3 , Laurence McEvoy  1 , Christopher Barton  1   4 , Susan Picton  5 , Simon Bailey  6 , Penelope Brock  7 , Harish Vyas  8 , David Walker  8 , Guy Makin  9 , Srinivas Bandi  10 , Barry Pizer  1   4 , Daniel B Hawcutt #  1 , Munir Pirmohamed #  1
Affiliations
Meta-Analysis

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity

Signe Thiesen et al. Pharmacogenet Genomics. 2017 Jun.

Abstract

Objectives: Cisplatin ototoxicity affects 42-88% of treated children. Catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic variants have been associated with ototoxicity, but the findings have been contradictory. The aims of the study were as follows: (a) to investigate these associations in a carefully phenotyped cohort of UK children and (b) to perform a systematic review and meta-analysis.

Methods: We recruited 149 children from seven UK centres using a retrospective cohort study design. All participants were clinically phenotyped carefully. Genotyping was performed for one ACYP2 (rs1872328), three TPMT (rs12201199, rs1142345 and rs1800460) and two COMT (rs4646316 and rs9332377) variants.

Results: For CTCAE grading, hearing loss was present in 91/120 (75.8%; worst ear) and 79/120 (65.8%; better ear). Using Chang grading, hearing loss was diagnosed in 85/119 (71.4%; worst ear) versus 75/119 (63.0%; better ear). No TPMT or COMT single-nucleotide polymorphisms (SNPs) were associated with ototoxicity. ACYP2 SNP rs1872328 was associated with ototoxicity (P=0.027; worst ear). Meta-analysis of our data with that reported in previous studies showed the pooled odds ratio (OR) to be statistically significant for both the COMT SNP rs4646316 (OR: 1.50; 95% confidence interval: 1.15-1.95) and the ACYP2 SNP rs1872328 (OR: 5.91; 95% confidence interval: 1.51-23.16).

Conclusion: We showed an association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, but not with the TPMT and COMT. A meta-analysis was statistically significant for both the COMT rs4646316 and the ACYP2 rs1872328 SNPs. Grading the hearing of children with asymmetric hearing loss requires additional clarification.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have not competing interests to disclose.

Figures

Figure 1
Figure 1
A-F Meta-analyses of associations between genetic variants of TMPT, COMT and ACYP2 and ototoxicity
Figure 1
Figure 1
A-F Meta-analyses of associations between genetic variants of TMPT, COMT and ACYP2 and ototoxicity
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McHaney V, Thibadoux G, Hayes F, Green A. Hearing loss in children receiving cisplatin chemotherapy. The Journal of pediatrics. 1983;102(2):314–317. - PubMed
    1. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear and hearing. 1998;19(5):339–354. - PubMed
    1. Walker D, Pillow J, Waters K, Keir E. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Medical and pediatric oncology. 1989;17(1):48–52. - PubMed
    1. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology. 1989;7(6):754–760. - PubMed
    1. Li Y, Womer R, Silber J. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer. 2004;40(16):2445–2451. - PubMed

MeSH terms